Fagron, the leading global player in pharmaceutical compounding, announces that the Brazilian competition authority, CADE, has granted clearance for the previously announced acquisitions of Purifarma and Injeplast in Brazil.

The clearances represent an important step forward in executing Fagron’s disciplined M&A strategy in Latin America. The transactions will broaden Fagron’s portfolio and capabilities in Brazil, supporting the Group’s ambition to build a scalable, high-quality platform aligned with its long-term growth objectives.

Purifarma operates a highly concentrated Essentials portfolio at very large volumes, presenting significant potential to improve profitability within 18 months post-closing through enhanced product portfolio and brands expansion, as well as increased operational leverage and procurement savings. In addition, the scale-up is expected to generate procurement benefits not only across Latin America but throughout our entire global footprint.

Injeplast will further strengthen Fagron’s vertical integration by producing high-quality packaging solutions and efficient manufacturing processes, supporting our Essentials strategy by broadening our product portfolio and customer base in Latin America as well as other regions.

Completion of the acquisitions remains subject to customary closing conditions and completion of certain local corporate and contractual formalities.

Rafael Padilla, CEO of Fagron, commented: “CADE’s approvals allow us to progress towards closing Purifarma and Injeplast. These acquisitions strengthen our leadership position in Brazil and complement our strategy to combine targeted M&A with operational excellence while maintaining financial discipline.”